The blood-based test is intended to aid in the decision for prostate biopsy for men older than 50 with elevated PSA levels.

Of the 30 companies in the index, 25 saw their share prices increase and four saw their stock prices decline, while one company was flat month over month.

The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.

The agency would down-classify nucleic acid-based tests for use with a corresponding approved therapy product to Class II devices from Class III.

InnotiveDx's UTI diagnostic technology provides bacterial identification and antimicrobial susceptibility test results in less than 60 minutes.

The test is expected to be used by payors and healthcare systems to identify people most likely to respond to the weight-loss drugs.

The pre-Series A funding round was led by Spectrum Impact with participation from the founders and existing investors including Vijay Alreja Family Office.

The company beat analysts' average estimates on the top and bottom lines and guided to $7.3 billion to $7.4 billion in revenues for fiscal 2026.